Hellmann MD, Ott PA, Zugazagoitia J, et al. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. J Clin Oncol. 35, 2017 (suppl; abstr 8503).
PFS-voordeel van durvalumab plus olaparib bij gevorderd ovariumcarcinoom zonder BRCA-mutatie
mrt 2026 | Gynaecologische oncologie